The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Emerging applications for ferumoxytol as a contrast agent in MRI
Open accessAbstract
Ferumoxytol is an ultrasmall superparamagnetic iron oxide (USPIO) agent initially approved by the Food and Drug Administration (FDA) as an iron replacement therapy for patients with anemia due to chronic renal failure. Recently, ferumoxytol has been investigated extensively as an intravenous contrast agent in magnetic resonance imaging (MRI). Since it causes regional T1 and T2* shortening in vivo, conventional pulse sequences can be used following ferumoxytol administration to demonstrate signal enhancement or loss. Ferumoxytol can be administered as a rapid bolus and has a long intravascular half‐life on the order of 14–15 hours, making it a potentially useful agent for vascular and perfusion‐weighted MRI. In comparison to other USPIOs, ferumoxytol is less limited by allergic and idiosyncratic reactions. Furthermore, since ferumoxytol is an iron‐based agent with no potential for causing nephrogenic systemic fibrosis, it may be useful as an alternative to gadolinium‐based contrast agents in patients with compromised renal function. Ferumoxytol is ultimately taken up by macrophages/the reticuloendothelial system in the liver, spleen, and lymph nodes, and this uptake mechanism is being explored as a novel imaging technique for vascular lesions, tumors, and lymph nodes. This article reviews the properties of ferumoxytol relevant to MRI as well as many of the uses for the agent currently under investigation. J. Magn. Reson. Imaging 2015;41:884–898. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Circulation · doi:10.1161/01.cir.92.5.1355 · Cited by 3,533
Naghavi, M., Libby, P., Falk, E., Casscells, S. W., Litovsky, S., Rumberger, J., Badimon, J. J., Stefanadis, C., Moreno, P., Pasterkamp, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000087480.94275.97 · Cited by 2,270
Grobner, T. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfk062 · Cited by 1,859
Rohrer, M., Bauer, H., Mintorovitch, J., Requardt, M., & Weinmann, H.-J. (2005) · Investigative Radiology · doi:10.1097/01.rli.0000184756.66360.d3 · Cited by 1,682
Agnelli, G., Anderson, F., Arcelus, J., Bergqvist, D., Brecht, J., Greer, I., Heit, J., Hutchinson, J., Kakkar, A., Mottier, D., et al. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-03-0212 · Cited by 1,566
Current Concepts of the Pathogenesis of the Acute Coronary Syndromes
Libby, P. (2001) · Circulation · doi:10.1161/01.cir.104.3.365 · Cited by 1,558
Recent advances in iron oxide nanocrystal technology for medical imaging☆
COROT, C., ROBERT, P., IDEE, J., & PORT, M. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.013 · Cited by 1,465
Marckmann, P., Skov, L., Rossen, K., Dupont, A., Damholt, M. B., Heaf, J. G., & Thomsen, H. S. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006060601 · Cited by 1,400
Wood, J. C., Enriquez, C., Ghugre, N., Tyzka, J. M., Carson, S., Nelson, M. D., & Coates, T. D. (2005) · Blood · doi:10.1182/blood-2004-10-3982 · Cited by 1,045
Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation
Sadowski, E. A., Bennett, L. K., Chan, M. R., Wentland, A. L., Garrett, A. L., Garrett, R. W., & Djamali, A. (2007) · Radiology · doi:10.1148/radiol.2431062144 · Cited by 1,018
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
Wahsner, J., Gale, E. M., Rodríguez-Rodríguez, A., & Caravan, P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00363 · Cited by 1,603
A Review of Clinical Translation of Inorganic Nanoparticles
Anselmo, A. C., & Mitragotri, S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9780-2 · Cited by 509
Metadata
- Authors
- Bashir, M. R., Bhatti, L., Marin, D., & Nelson, R. C.
- Venue
- Journal of Magnetic Resonance Imaging
- Publisher
- Wiley
- Published
- 2014-06-30
- Volume
- 41
- Issue
- 4
- Pages
- 884-898
- ISSN
- 1053-1807 (ISSN-L)
- 1522-2586
- OpenAlex
- W1937451961
- Cited by
- 371
- References
- 81
- FWCI
- 25.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging applications for ferumoxytol as a contrast agent in MRI. https://app.cochat.ai/papers/10.1002/jmri.24691
- The paper
- Bashir, M. R., Bhatti, L., Marin, D., & Nelson, R. C. (2015). Emerging applications for ferumoxytol as a contrast agent in MRI. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.24691
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.